Regeneron Ophthalmology Deal History & Licensing Activity
Regeneron Ophthalmology is a large biotech headquartered in US. Over the past three years, Regeneron Ophthalmology has been involved in 2 licensing and acquisition transactions, with a primary focus on Radiopharmaceuticals (2 deals).
Deals (12mo)
2
Active Trials
25
Top Modality
Radiopharmaceuticals
Focus Area
Oncology
Regeneron Ophthalmology Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Regeneron Ophthalmology in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Telix Pharmaceuticals radiopharma pact | Regeneron | Radiopharmaceuticals | Unknown | collaboration | Jun 12, 2026 |
| Parabilis ADC platform | Regeneron | ADC | Discovery | collaboration | May 18, 2026 |
Regeneron Ophthalmology Pipeline Focus
Therapeutic areas and modalities where Regeneron Ophthalmology is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Regeneron Ophthalmology Strategic Signals
Key indicators of Regeneron Ophthalmology's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Regeneron Ophthalmology's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Radiopharmaceuticals Benchmarks
Upfront, milestone, and royalty benchmarks for radiopharmaceuticals deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Regeneron Ophthalmology Licensing & Deal Activity
Regeneron Ophthalmology is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Regeneron Ophthalmology ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Regeneron Ophthalmology include Oncology (4 deals and trials). In terms of modality, Regeneron Ophthalmology has shown particular interest in radiopharmaceuticals, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Regeneron Ophthalmology and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Regeneron Ophthalmology's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.